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ABSTRACT
Virusesarereplicationcompetentgenomeswhichare
relatively gene-poor. Even the largest viruses (i.e.
Herpesviruses) encode only slightly .200 open read-
ing frames (ORFs). However, because viruses repli-
cate obligatorily inside cells, and considering that
evolution may be driven by a principle of economy of
scale, it is reasonable to surmise that many viruses
have evolved the ability to co-opt cell-encoded
proteins to provide needed surrogate functions. An
in silico survey of viral sequence databases reveals
that most positive-strand and double-stranded RNA
viruses have ORFs for RNA helicases. On the other
hand, the genomes of retroviruses are devoid of
virally-encoded helicase. Here, we review in brief the
notion that the human immunodeficiency virus (HIV-
1) has adopted the ability to use one or more cellular
RNA helicases for its replicative life cycle.
INTRODUCTION
Helicases are enzymes that separate in an energy-dependent
manner stretches of duplexed DNA and/or RNA into single-
stranded components. Currently, based on characteristic
motifs and the sequence comparisons, three superfamilies
(SF1 through 3) and two smaller families (F4, F5) of heli-
cases have been identiﬁed (1). Superfamily 1 and 2 contain
helicases which share seven or more recognized signature
amino acid motifs while SF3 and F4 and F5 helicases are
characterized generally by three conserved motifs (2); the
F4 and F5 proteins are largely bacterial and bacteriophage
proteins. Currently, it should be cautioned that many ‘heli-
cases’ are not bona ﬁde helicases, but may only function as
RNA translocases, perhaps to fulﬁll functions in the remodel-
ing of ribonucleoprotein complexes (RNP).
DEAD-box and the related DEAH, DExH and DExD (3)
helicases are the most numerous members of SF2 and are
ubiquitously present in eukaryotic genomes. These helicases
share eight conserved motifs and are commonly refered to
as the DExH/D family of helicases. Humans, Arabidopsis
and Saccharomyces have  38, 55 and 25 such entities,
respectively (4). Differing from DNA helicases and DExH
proteins, DEAD helicases are poor in unwinding long nucleic
acid duplexes and are best suited for separating short RNA
hybrids. DEAD-box proteins bind with high-afﬁnity RNA–
protein complexes while exhibiting little RNA sequence pref-
erence. This suggests that the speciﬁcity determinants for
DEAD helicases may be through the recognition of protein
factors. In this regard, a better understanding of the roles
for DEAD proteins depends on the clear characterization of
their respective interacting proteins.
Although the precise substrate for most helicases awaits
deﬁnition, DEAD helicases are generally thought to partici-
pate pleiotropically in many aspects of RNA metabolism
including transcription, mRNA splicing, mRNA export, trans-
lation, RNA stability and mitochondrial gene expression
(5–8). Some examples of helicases and their attributed func-
tions include the following. UAP56, Brr2, Prp16, Prp22 and
Prp43 play roles in RNA-splicing (4,9), while Dbp5 (10,11)
and DDX3 (12) chaperone RNAs from the nucleus into the
cytoplasm. eIF4a and Ded1 serve for translation of mRNAs
while Rh1B, Ski2, Dob1, Dhh1 helicases contribute to
mRNA stability (4). Other DEAD helicases act in ribosome
biogenesis through regulation of small nucleolar RNAs and
ribosomal RNAs (rRNAs) interactions (13,14). Finally,
Neurospora and Trypanosoma DEAD proteins contribute to
mitochondrial gene expression (15,16); a Cryptococcus
DEAD helicase is required for cryptococcosis pathogenesis
(17), and the dipteran Chironomus tentans uses a hrp84
DEAD helicase to regulate mRNA transport from the nucleus
into the cytoplasm onto polyribosomes (18).
Given that helicases signiﬁcantly contribute to normal
cellular metabolism, are they similarly essential to viruses?
The operational answer appears to be a qualiﬁed ‘yes’.
Indeed, when DEAD/DEAH-box helicase motif (InterPro
IPR001410) was used to search the EMBL-EBI database,
1561 matches to individual viral sequence entries were
found (http://www.ebi.ac.uk/interpro/DisplayIproEntry?ac¼
IPR001410), suggesting that many viruses have evolved to
encode directly helicase or helicase-like proteins. The stron-
gest biological evidence which supports the importance of a
helicase in the virus life cycle comes from those viruses
with an RNA genome. Hence, all positive-strand RNA
viruses encode one or more helicase/helicase-like open read-
ing frame (ORF) which, aside from the RNA-dependant RNA
polymerase, is the most highly conserved viral sequence.
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types of viruses (see some examples listed in Table 1). Direct
mutagenesis studies have conﬁrmed that a helicase function is
biologically required for the replication of many viruses
including vaccinia virus (19), poliovirus (20), alphaviruses
(21), brome mosaic virus (22), nidoviruses (23,24) and
ﬂaviviruses (25–27).
ROLE OF HELICASE IN THE HIV-1 LIFE CYCLE
In 1981, the ﬁrst cases of acquired immunodeﬁciency
syndrome (AIDS) were described in American homosexual
men. Thereafter, within three short years, French and Amer-
ican scientists conﬁrmed that the human immunodeﬁciency
virus (HIV) is the causative agent for AIDS. In the ensuing
20 years, >20 million individuals have died from AIDS;
and currently, in 2006,  50 million people worldwide are
infected by HIV-1 with 3 million incremental AIDS deaths
and 4–5 million new infections occurring annually. The
magnitude of this burden casts urgency to medical research
on HIV/AIDS.
HIV-1 is a retrovirus of the lentivirus genus with an RNA
genome of  9 kilobases which encodes nine polypeptides.
The major HIV-1 structural proteins are encoded by three
genes, gag (group-speciﬁc antigen), pol (polymerase) and
env (envelope), while the accessory proteins, Vif, Vpu, Vpr
and Nef, and the regulatory proteins, Tat and Rev, are the
primary translation products of multiply-spliced mRNA.
HIV-1 infects CD4+ human T-cells and macrophages and
integrates as a provirus into the host cell’s DNA. Gene
expression of HIV-1 is governed transcriptionally by a viral
protein, Tat (28,29), via its binding to a nascent viral TAR
RNA (30), and post-transcriptionally by a second viral pro-
tein Rev (31,32) through its association with the viral RRE
RNA. Both Tat and Rev interact with several host cell pro-
teins in their transcriptional and post-transcriptional functions
(33). HIV-1 does not encode for any RNA helicase; however,
ﬁndings suggest that host cell RNA helicases may be
involved in the reverse transcription of HIV-1 RNA, in
HIV-1 mRNA transcription and in the nucleus-to-cytoplasm
transport of viral mRNA.
A recent unexpected ﬁnding revealed the possibility that an
RNA helicase may potentially contribute roles in HIV-1 par-
ticle assembly and reverse transcription (34). Using pro-
teomic analyses, Roy et al. (34) reported that the DEAH
protein RNA helicase A (RHA) was found associated with
HIV-1 Gag and packaged into HIV-1 virions in an RNA-
dependent manner. When RHA was knocked down in cells,
HIV-1 particles which were produced from these cells were
signiﬁcantly less infectious. This appears to be compatible
with two possible explanations. First, it is conceivable that
RHA participates in the formation of infectious virus particles
either by shaping Gag–RNA interaction during viral particle
assembly or by budding. Failure of RHA to properly restruc-
ture viral RNP could explain the observed reduced infectiv-
ity. Second, Roy et al. (34) reported evidence that HIV-1
particles that do not contain RHA showed reduced virion-
endogenous reverse transcriptase activity. In this respect, it
may be that RHA assists HIV-1 reverse transcriptase to
more efﬁciently copy RNA by unwinding RNA secondary
structure or by promoting the interaction of viral RNA with
the nucleocapsid protein in order to assemble a better reverse
transcription complex.
Separate from reverse transcription, the unwinding of
highly structured RNAs might also be reasoned to be impor-
tant for transcription (35). However, direct evidence for an
RNA helicase role has been somewhat elusive. There are sev-
eral examples which seemingly support an activity for RNA
helicase in transcription. First, in vaccinia virus, it has been
postulated that the NPH-II helicase assists transcription by
strand-separating duplexed RNA structures to prevent
R-loop formation behind the elongating RNA polymerase
(36). Second, RHA has been invoked to provide a factor-
recruitment role, bridging at the promoter the CREB-binding
protein (37) and RNA polymerase II (37). Third, the p68
DEAD-box helicase was shown recently to be a novel tran-
scriptional co-activator for p53’s transcriptional function
(38). Interestingly, in the latter two instances, neither the
ATPase nor the helicase activity of RHA and p68 is appar-
ently required for their attributed transcriptional roles.
For HIV-1, two recent studies provide clues that RNA heli-
cases may also serve co-factor function for transcription from
the viral long terminal repeat (LTR). Fujii et al. (39) observed
that RHA conserves in its N-terminus two double-stranded
RNA-binding (dsRBD) domains characterized previously
for the TAR RNA-binding protein, TRBP (40,41). These
investigators found in both reporter and virus replication
assays that RHA activated, in a TAR RNA-binding dependant
manner, HIV-1 LTR-directed transcription (39). Next,
Cocude et al. (42) separately described that the expression
of a DExH RNA helicase, RH116, was signiﬁcantly induced
after infection of HeLa-CD4 cells by HIV-1. RH116 was
found localized in the nucleus of HIV-1 infected cells and
was observed to augment the transcription of unspliced
HIV-1 transcripts. While both studies offer tantalizing
evidence for roles by two different RNA helicases in HIV-1
transcription, critical details on how the helicases function by
binding to TAR RNA and how this binding might cooperate
with the activities of the viral transcriptional activator, Tat,
are lacking. Pending more direct experimental tests, it
remains unclear whether RHA and RH116 provide direct
Table 1. Examples of viral helicases
Sources Superfamily 1 Superfamily 2 Superfamily 3
Animal DNA
virus
UL5 (Herpesvirus) UL9 (Herpesvirus) NPH-II (Poxvirus) E1 (91) T antigen (SV40) NS1 (Parvovirus)
Animal RNA
virus
NSP2 (Alphavirus)
p70 (Rubella virus) Nsp13
(SARS) ORF-1 (Hepatitis E)
NS3 (Flavivirus) NS3
(Hepatitis C virus) NS3 (Pestivirus)
2C (19) 2C (Hepatitis A virus) 2C (Rhinovirus)
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polymerase II initiation/elongation at the LTR.
Downstream from transcription, the fate of HIV-1 encoded
RNA is regulated at the step of export of unspliced/partially
spliced moieties from the nucleus into the cytoplasm.
Unspliced and partially spliced viral RNAs code for genomic
RNAs that are packaged into progeny virions and structural
proteins. Hence, the egress of these RNAs from the nucleus
into the cytoplasm is critical to the life cycle of the virus.
Exit of HIV RNAs from the nucleus is a signiﬁcant issue
because unspliced/partially spliced cellular mRNAs are rou-
tinely retained in and not permitted export from the nucleus
(43–46). A large body of work has suggested an elegant
solution to this conundrum. Thus, it was established that
the HIV-1 encoded Rev protein binds a highly secondary
structured element (Rev responsive element; RRE) present
in all unspliced and partially spliced HIV transcripts
(47–57); and this binding speciﬁcally distinguishes, for pur-
poses of nuclear export, viral transcripts from cellular RNAs.
New evidence now suggests that RNA helicases are also
co-factors for Rev-directed export of HIV-1 mRNAs (58).
In its role of transporting unspliced and incompletely spliced
viral RNAs from the nucleus, Rev directly interacts with
nuclear export receptor CRM1 (59,60), and CRM1 is required
for Rev-mediated export of HIV RNAs (59,61,62). A recent
report provides data that an RNA helicase, DDX3, is an addi-
tional player in the Rev–CRM1–RRE complex (12). Thus, it
was shown that DDX3 over-expression enhanced Rev-
dependent, but not other export, pathway; and that DDX3 is
a nucleo-cytoplasmic shuttling protein which binds CRM1
and Rev. Moreover, DDX3’s necessity for Rev/RRE/CRM1
function was demonstrated by knock-down of cell endoge-
nous DDX3. Finally, because DDX3 locates to nuclear pore
complexes (NPC), Yedavalli et al. (12) further proposed
that this human helicase, like the analogous yeast Dbp5p
(11), may function with Rev/CRM1 to remodel and ‘thread’
large unspliced HIV-1 RNAs through the nuclear pore, facili-
tating their ﬁnal release to the cytoplasmic side of the NPC.
The above DDX3 results are consistent with two additional
papers which described similar ﬁndings for a related RNA
helicase, DDX1. Thus, Pomerantz and co-workers (63)
showed that DDX1 binds directly to the N-terminus of Rev
and to the RRE-RNA motif and participates in the export
of unspliced HIV-1 RNA from the nucleus to the cytoplasm.
Additionally, they illustrated that reduced expression of
DDX1 in astrocytes explains the previously observed tissue
restricted function of HIV-1 Rev (64). Fully spliced viral
mRNAs encoding for viral Tat, Rev and Nef, proteins have
been shown previously to exit the nucleus using the cellular
mRNA export pathway. Export of these mRNA may require
the RNA helicase Dbp5 (65,66). As yet, the involvement of
Dbp5 in export of spliced HIV-1 viral RNA has not been
fully clariﬁed.
The story of HIV-1 and RNA helicases is, however, likely
to be more complex than and unlikely to conclude simply
with RHA, RH116, DDX1 and DDX3 (Figure 1). HIV-1
RNAs are extensively regulated through splicing. Splicing
is a multiple-step process requiring the recognition of splice
sites by spliceosomes. It is generally believed that remodeling
of RNA–RNA and RNA–protein interactions within the
spliceosome is catalyzed by a family of DEAD/DExH box
RNA helicases. To date, seven mammalian proteins that are
RNA helicases have been implicated in mRNA splicing
(67,68). Whether there is speciﬁc preference by subclasses
of RNA helicases for viral mRNA splicing remains to be
clariﬁed. Moreover, how cellular RNA helicases might
contribute to the translation of viral mRNAs also require
further investigation.
Recently both Van’t Wout et al. (69) and Krishnan and
Zeichner (70) have provided evidence that the expression of
several cellular RNA helicases including DDX24, DDX21,
DDX18, DDX11 and DDX9 is modulated during HIV-1
infection; however, the precise cellular role and signiﬁcance
of these helicases for HIV-1 pathogenesis have not be charac-
terized. Interestingly, Krishnan and Zeichner reported
microarray data which examined the transition of HIV-1
infection from latency to productive replication, and found
that several cellular RNA helicases were upregulated (71).
For future understanding of functions, it will be important
to design experiments which can segregate helicases which
serve direct, although perhaps overlapping and redundant,
roles on HIV-1 from those that might participate indirectly
in the viral life cycle. Nevertheless, the convergence of evi-
dence would support that several discrete cellular RNA heli-
cases contribute importantly to the efﬁcient execution of
several steps in the HIV-1 replicative cycle.
HELICASE INHIBITORS AS FUTURE
ANTIVIRALS?
Given that the HIV-1/AIDS disease burden has reached pan-
demic global proportions, new antiviral strategies that target
molecularly delineated mechanisms used by this virus are
urgently needed (72). Is there a possibility that host cell heli-
cases can be therapeutic targets for anti-HIV-1
chemotherapy? Implicit within this question is the concept
that one could attack a host cell protein in order to treat an
infecting pathogen. Although targeting a cellular protein
involved in a viral pathway risks obvious cytotoxicity, this
approach avoids the inherent problem posed by rapid HIV-1
mutation to all currently utilized chemotherapeutics tar-
geted to virus-encoded proteins. We note that inhibition of
cell-encoded enzymes in medical therapy is not an unprece-
dented strategy. Suppression of angiotensin-converting
enzyme (ACE) is widely used to treat hypertension, conges-
tive heart failure, myocardial infarction, endothelial dysfunc-
tion and renal disease (73). Elsewhere, aromatase inhibitors
have been used to treat hormone-dependent breast cancer
(74), and inhibitors of cellular secretory proteases are con-
templated for Alzheimer’s disease (75). We recently inhibited
the cellular polyprotein convertase, furin, at minimal toxicity
to the cell in order to block HIV-1 replication (76). Thus, a
priori exclusion of cellular helicase as an antiviral target is
not warranted.
Guarded optimism that small molecule helicase inhibitors
can be developed against viruses arises from encouraging
progress in non-retroviral systems. Unlike HIV-1, human her-
pesviruses physically encode helicases. The herpes simplex
virus UL5 and UL9 genes are helicases in superfamily 1
and 2, respectively (77). HSV UL5 together with UL8 and
UL52 form a heterotrimeric helicase–primase complex
4200 Nucleic Acids Research, 2006, Vol. 34, No. 15responsible for unwinding duplex viral DNA at replication
forks. Two recent studies provide proof-of-concept that the
HSV helicase–primase can be targeted at low host cell
toxicity by two new classes of drugs, amino-thiazolyphenyl-
molecules (78) and thiazole amide derivatives (79). In
addition, other studies suggest that the NS3 protein, a RNA
helicase encoded by Hepatitis C virus and related West
Nile virus and Japanese Encephalitis virus can be targeted
to inhibit viral replication (80–82). This conceptual break
through in drug development is important because it indicates
Figure 1. Schematic representation of the involvement of cellular RNA helicases in reverse transcription, transcription and post-transcriptional regulation of
HIV-1 RNAs. RHA has been found to be a part of the HIV-1 virion and may participate in HIV-1 reverse transcription as well as particle assembly. RHA and
RH116 have been reported to participate in HIV-1 transcription through interaction with the viral leader RNA, TAR. DDX1 and DDX3 act with Rev and RRE-
containing RNAs for the transport of unspliced and partially spliced HIV-1 RNA from the nucleus to the cytoplasm.
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by small molecule inhibitors is possible. Of relevance to
HIV-1, a synthetic immunomodulator Murabutide was
shown recently to suppress HIV-1 replication in macrophages
and T cells. Murabutide was shown to inhibit the activity of
RNA helicase RH116, blocking its positive transcriptional
activity for HIV-1 gene expression (42).
If one looks beyond the signature motifs conserved
amongst helicases, then it becomes clear that the different
proteins are widely divergent in their coding sequences.
In principle, this suggests that individual helicases can be
abrogated with speciﬁcity in a knowledge-directed manner.
In theory, a helicase can be attacked by (i) inhibition of
NTPase activity through direct competition for NTP binding,
(ii) inhibition of substrate binding through direct competition
at active site, (iii) allosteric mechanisms to affect NTP-
binding/NTP hydrolysis and/or polynucleotide binding, and
(iv) inhibition of unwinding activity by steric hinderance of
helicase translocation along the polynucleotide substrate
(83,84). Because the NTP-binding and substrate-binding
pockets may be sufﬁciently similar between various heli-
cases, speciﬁcity of inhibition through these sites will likely
be extremely difﬁcult, although perhaps not impossible. On
the other hand, the tremendous variations in sequence and
Figure 2. Involvement of Dicer RNA helicase, TRBP and HIV-1 TAR RNA in the biology of the cell’s micro RNA pathway. (A) Domain structure of Dicer
proteins from mammals and Drosophila.( B) A schematic representation of a potential mechanism for TAR RNA-dependent suppression of Dicer activity. TAR
RNA is suggested to bind to TRBP and decoy it from Dicer preventing Dicer-dependent miRNA processing activity.
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crete domains responsible for protein–protein interactions
and/or for targeting to speciﬁc nucleic acids (85), and in
their differential localizations within cells (86) offer interven-
tional possibilities outside of the NTP- or polynucleotide-
binding sites.
We are in the preliminary stages of screening ring-
expanded nucleoside analogs found previously to be success-
ful NTPase/helicase inhibitors of West Nile virus, Hepatitis C
virus and Japanese encephalitis virus (81,82). We have
observed that a few of these candidate inhibitors have
substantial anti-HIV-1 activity at doses that do not incur
cytotoxicity to cells treated in tissue culture for 1 week.
Further studies are needed before concluding that these
compounds exert speciﬁc inhibition of DDX3, one of the
other cellular helicases, or some other target altogether.
CONCLUDING REMARKS AND PERSPECTIVES
There is another area where a cellular helicase activity and
HIV-1 are likely to intersect. An emerging research focus is
the role of small interfering RNAs (87) and microRNAs
(miRNA) as innate cell defenses against viruses including
HIV-1 (87–90). In human cells, the precursor for miRNA
(pre-miRNA) is processed by DICER (Figure 2A) which is
a ribonuclease with a bona ﬁde RNA helicase domain
(91,92). A surprising recent ﬁnding revealed that the human
TRBP, which has been shown to be a potent binder of the
HIV-1 TAR RNA RNA (40,41), is an indispensable
dsRNA-binding partner of DICER which allows the latter
to associate with pre-miRNA (91,92). Without TRBP,
DICER’s miRNA processing activity is lost. Thus an intri-
guing scenario can potentially unfold. Accordingly, whereas
the ribonuclease–helicase protein DICER requires TRBP to
process duplex-structured miRNAs in order that the cell can
use such matured miRNAs for antiviral defense, it could be
speculated that HIV-1 has evolved to restrict this defense
by the ability to transcribe viral TAR RNA to squelch
TRBP away from DICER (Y. Bennasser, M. L. Yeung and
K. T. Jeang, manuscript submitted) (Figure 2B). If this think-
ing is correct, then HIV-1 has developed mechanisms not
only to co-opt the active functions of a virus-propitious cellu-
lar helicase (i.e. DDX3) but also to inactivate the role of a
second virus-pernicious helicase (i.e. DICER) for purposes
of selﬁsh gain.
In a separate perspective, virus infection can trigger
through double-stranded viral RNAs an innate antiviral
immune response. Thus viral dsRNAs can be recognized by
cellular proteins [pattern-recognition receptors (PRRs)]
which initiate antiviral responses by inducing the production
of a variety of cytokines including type I interferons (IFN-a
and IFN-b) and initiating additional inﬂammatory and adap-
tive immune responses. Recently, DExD/H RNA helicases
such as RIG-1 (retinoic acid inducible gene-1) (93) and
Mda5 (melanoma differentiation-associated gene 5) (94)
have been identiﬁed as suppressors of viral replication by
binding to virus associated dsRNA and activating type I
interferon-dependent antiviral immunity. Over-expression of
RIG-1 and Mda5 was found to enhance dsRNA induced
type I interferon antiviral response. Currently, it remains
speculative whether helicases like RIG-1 and Mda5 may rec-
ognize HIV-1 dsRNA and trigger an innate immune response.
Intriguingly, several reports exist in the literature that HIV-1
infection does induce activation of type 1 interferons (95,96).
In conclusion, by studying helicase proteins one can gain
insights into normal cellular metabolic processes, abnormal
inherited human diseases (e.g. Bloom syndrome, Werner syn-
drome, Cockayne’s syndrome and xeroderma pigmentosum;
all diseases with mutations in cellular helicases), and remark-
ably also the biology of viruses.
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